semagacestat   Click here for help

GtoPdb Ligand ID: 6978

Synonyms: LY-450139
PDB Ligand
Compound class: Synthetic organic
Comment: Semagacestat is a small-molecule γ-secretase inhibitor that was developed by Eli Lilly as a potential treatment for Alzheimer's disease but it failed in Phase 3 clinical trials. NOTCH is also a γ-secretase substrate [3], and on-target inhibition of NOTCH receptor-related signalling by semagacestat treatment is proposed to be (at least in part) responsible for the unacceptable side effects that were noted in clinical trials, and which lead to termination of the trials [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 3
Rotatable bonds 7
Topological polar surface area 98.74
Molecular weight 361.2
XLogP 0.72
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(C(NC(=O)C(C(C)C)O)C)NC1C(=O)N(C)CCc2c1cccc2
Isomeric SMILES O=C([C@@H](NC(=O)[C@H](C(C)C)O)C)N[C@@H]1C(=O)N(C)CCc2c1cccc2
InChI InChI=1S/C19H27N3O4/c1-11(2)16(23)18(25)20-12(3)17(24)21-15-14-8-6-5-7-13(14)9-10-22(4)19(15)26/h5-8,11-12,15-16,23H,9-10H2,1-4H3,(H,20,25)(H,21,24)/t12-,15-,16-/m0/s1
InChI Key PKXWXXPNHIWQHW-RCBQFDQVSA-N
No information available.
Summary of Clinical Use Click here for help
The Phase 3 trial was stopped because, compared with placebo, semagacestat did not improve cognitive status and patients receiving the higher dose had significant worsening of functional ability. [1]